Thousand-And-One Kinase 3 in Pancreatic Ductal Adenocarcinoma Stemness, Microenvironment and Therapy Resistance

Pancreatic ductal adenocarcinoma (PDA) remains one of the most recalcitrant solid tumors, characterized by a fibrotic and immunosuppressive tumor microenvironment (TME), inherent chemoresistance and systemic cachexia. Recent pan-cancer proteomic and transcriptome analyses have identified Thousand-and-one amino acid kinase 3 (TAOK3) as a central signaling node governing these lethal hallmarks. Operating as a MAP kinase kinase kinase (MAP3K) within the STE20 family, TAOK3 coordinates diverse cellular processes. In the PDA parenchyma, TAOK3 maintains the cancer stem cell (CSC) phenotype by enforcing a strict DNA damage response checkpoint. Within the TME, TAOK3 facilitates local invasion by regulating endosomal trafficking for invadopodia assembly. Furthermore, TAOK3 exerts immunomodulatory effects, dictating macrophage polarization and preserving canonical T-cell receptor (TCR) signaling by inducing the degradation of the SHP-1 phosphatase. Systemically, tumor-derived signals establish a pathogenic feedforward loop with skeletal muscle whereby TAOK1 activity is upregulated in peripheral skeletal muscle to drive muscle atrophy secondary to TAOK3 expression in the primary tumor. The recent development of specific structural inhibitors with dual-acting natural bioactivities, provides a compelling preclinical foundation to transition TAOK3 from prognostic biomarker to premier therapeutic target in pancreatic oncology.